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ORIGINAL ARTICLE
The spectrum of COVID-19eassociated
dermatologic manifestations: An
international registry of 716 patients
from 31 countries
Esther E. Freeman, MD, PhD,a,b Devon E. McMahon, BA,a Jules B. Lipoff, MD,c Misha Rosenbach, MD,c
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Background: Coronavirus disease 2019 (COVID-19) has associated cutaneous manifestations.
Objective: To characterize the diversity of cutaneous manifestations of COVID-19 and facilitate
understanding of the underlying pathophysiology.
Methods: Case series from an international registry from the American Academy of Dermatology and
International League of Dermatological Societies.
Results: The registry collected 716 cases of new-onset dermatologic symptoms in patients with confirmed/
suspected COVID-19. Of the 171 patients in the registry with laboratory-confirmed COVID-19, the most
common morphologies were morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%),
vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%). Pernio-like lesions were common in
patients with mild disease, whereas retiform purpura presented exclusively in ill, hospitalized patients.
Limitations: We cannot estimate incidence or prevalence. Confirmation bias is possible.
Conclusions: This study highlights the array of cutaneous manifestations associated with COVID-19. Many
morphologies were nonspecific, whereas others may provide insight into potential immune or inflammatory
pathways in COVID-19 pathophysiology. ( J Am Acad Dermatol https://doi.org/10.1016/j.jaad.2020.06.1016.)
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COVID-19, caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), has associated
cutaneous manifestations.1 Case series have docu-
mented pernio-like lesions,2-7 erythematous macules
or papules,5,6,8 urticarial,8,9 morbilliform,9 varicelli-
form,5,6,8-10 papulosquamous,11 petechial erup-
tions,9,12 livedo reticularis-like rashes,5,9 purpuric
lesions,5 acro-ischemic
lesions,13 and retiform pur-
pura.14 The timing of erup-
tions in the disease course
and potential associations be-
tween morphologic subtypes
with different COVID-19eas-
sociated syndromes and/or
outcomes remain unclear.
Dermatologic manifesta-
tions of infectious diseases
are important for identifying
and treating viral illnesses
including HIV, dengue, and
chikungunya. Expert guid-
ance in recognizing these
signs represents an opportu-
nity to improve diagnosis and management.
Identification and characterization of COVID-19
skin lesions, like the well-described association
with anosmia, may prompt suspicion for SARS-
CoV-2 infection.15 Thus, dermatologists at Harvard
Medical School and Massachusetts General Hospital
created the COVID-19 Dermatology Registry and, in
collaboration with the American Academy of
Dermatology (AAD) and International League of
Dermatologic Societies (ILDS), invited health care
workers globally to submit data for possible cuta-
neous manifestations of confirmed or suspected
COVID-19.16
For this study, we aimed to (1) characterize
internationally representative cutaneous manifesta-
tions of confirmed/suspected COVID-19 and 2)
identify cutaneous manifestations that may provide
insight into the pathophysiology and disease course
of COVID-19.
METHODS
In collaboration with the AAD and ILDS, we
established an international registry to collect cases
of COVID-19 cutaneous manifestations (www.aad.
org/covidregistry); the registry is open to medical
professionals only, from any specialty.7 No protected
health information was collected, and all data were
deidentified. The registry collected COVID-19
diagnosis type (suspected vs laboratory confirmed),
demographics, comorbidities, dermatologic condi-
tion details, timing of symptoms, skin biopsy results,
COVID-19 symptoms and outcomes, including
hospitalization, oxygen and ventilator requirements,
and deaths. Providers were prompted by e-mail for
case updates.
Suspected or laboratory-confirmed COVID-19
cases with new-onset dermatologic findings
were eligible for inclusion in the initial
analysis. Patients whose
eruptions were identified as
drug induced by submitting
health care providers
were analyzed separately.
Additional analysis was per-
formed on the laboratory-
confirmed COVID-19 patient
subgroup. For patients with
pernio-like lesions, we
excluded those with prior
pernio history. Data were
analyzed by using Stata
(version 16). The Partners
Healthcare institutional re-
view board approved this
study, which did not meet
the definition of human subjects research.
RESULTS
From April 8 to May 17, 2020, 716 cases of
new-onset dermatologic manifestations in the setting
of confirmed/suspected COVID-19 were entered
into the registry by dermatologists (54%), other
physicians (32%), midlevel practitioners (7.3%),
nurses (2.8%), and other medical professionals
(3.4%). Cases were reported from 31 countries,
most (89%) from the United States. Seven cases
designated by providers as medication-induced
were analyzed separately and excluded from
subgroup analysis of laboratory confirmed cases
(Supplemental Table I; available via Mendeley at
http://doi.org/10.17632/gh945hpwy3.1), and 27
cases with prior pernio history were excluded. A
total of 171 cases (25%) were laboratory confirmed:
135 by polymerase chain reaction (PCR), 19 by
antibody, and 17 by unspecified testing (positive
result on COVID-19 laboratory assay, but the specific
test performed was unreported or unknown). The
median age of patients with laboratory-confirmed
COVID-19 was 44 years (interquartile range [IQR],
28-61), and 54% were female (Table I).
In the 171 patients with laboratory-confirmed
COVID-19, the most common morphologies were
morbilliform (22%), pernio-like (18%), urticarial
(16%), macular erythema (13%), vesicular (11%),
papulosquamous (9.9%), and retiform purpura
(6.4%) (for clinical photos, see Supplemental Fig 1;
CAPSULE SUMMARY
d In this international registry, the most
common dermatologic morphologies in
171 COVID-19 laboratory-confirmed
cases included morbilliform (22%),
pernio-like (18%), urticarial (16%),
macular erythema (13%), vesicular (11%),
papulosquamous (9.9%), and retiform
purpura (6.4%).
d Pernio-like lesions were noted in mild
disease, whereas retiform purpura was
seen exclusively in critically ill patients.
J AM ACAD DERMATOL
n 2020
2 Freeman et al
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
available via Mendeley at http://doi.org/10.17632/
gh945hpwy3.1). A subgroup analysis of patients sub-
mitted by dermatologists showed similar distribution
(Supplemental Table II; available via Mendeley at
http://doi.org/10.17632/gh945hpwy3.1). A minority
of patients presented with multiple morphologies,
including 4 cases of morbilliform plus urticarial rash,
and 2 cases of morbilliform plus pernio. Six reports
involvedmucousmembranes (4 of oral mucosa and 2
of conjunctivae). Of 17 reports of edema, most (71%)
were associated with another cutaneous finding.
Skin symptoms and affected body sites varied by
morphology (Table II). For example, morbilliform
morphologies were often pruritic and involved the
trunk, whereas pernio morphologies often caused
pain/burning and involved the feet/hands. The face
was involved in 21% of morbilliform rashes. Retiform
purpura were on the extremities and buttocks. The
full course of laboratory-confirmed rashes lasted a
median of 7 days (IQR, 3-10). Pernio, however, had a
longer course, with a median of 14 days (IQR, 8-24).
Full duration could be determined only for resolved
lesions. Most patients (72%) had ongoing lesions;
therefore, these values may underestimate duration.
Lesions generally occurred after (64%) or concur-
rent (15%) with other COVID-19 symptoms. In
particular, skin lesions occurred after COVID-19
symptoms for morbilliform (76%), pernio-like
(48%), urticarial (67%), macular erythema (57%),
vesicular (72%), papulosquamous (53%), and reti-
form purpura (91%) morphologies. A minority
occurred before other COVID-19 symptoms (12%).
Many patients with laboratory-confirmed COVID-
19 and dermatologic findings had no clear docu-
mented COVID-19 exposure (Table III). The most
common COVID-19 symptoms among laboratory-
confirmed cases included fever (61%) and cough
(59%). With respect to Centers for Disease Control
and Prevention (CDC)edefined PCR test qualifying
symptoms, patients with pernio-like skin lesions met
fewer CDC testing criteria, meeting 3 or more criteria
in 29%, compared to morbilliform eruptions (55%),
urticaria (70%), macular erythema (74%), or vesicular
eruptions (61%).17 An additional 8.8% of patients with
laboratory-confirmed COVID-19 were asymptomatic
aside from rash. Pernio-like lesions were not associ-
ated with other COVID-19 symptoms in 19%.
The most common medical comorbidities
included hypertension (16%), diabetes (12%), and
smoking (12%). Most patients did not receive
COVID-19especific treatment (60%). For the 69
patients receiving COVID-19 treatment, 55%
received antimalarial agents, and 50% received
antibiotics including azithromycin (56%), ceftriax-
one (37%), vancomycin (37%), piperacillin-
tazobactam (29%), and doxycycline (27%).
Treatment preceded the COVID-19eassociated
dermatologic condition in 56%. For morbilliform
rashes, 37% received no treatment, 15% received
treatment before morbilliform rashes started, and
48% received treatment after morbilliform rash onset.
Hospitalization varied: 16% of patients with
pernio-like lesions were hospitalized, compared to
35% for all other COVID-19 dermatologic manifes-
tations. Patients with retiform purpura tended to be
sicker; 100% were hospitalized and 82% had acute
respiratory distress syndrome (Table III and Fig 1).
For the 60 hospitalized patients with laboratory-
confirmed COVID-19, 24 (40%) required invasive
mechanical ventilation and/or extracorporeal mem-
brane oxygenation, and 17 (28%) required supple-
mental oxygen. Themost common complicationwas
acute respiratory distress syndrome, in 23 (38%). Ten
patients died, including those with morbilliform rash
and macular erythema (n = 2), urticaria (n = 1),
acrocyanosis and pernio-like lesions (n = 1), acro-
cyanosis (n = 1), livedo-reticularis (n = 1), retiform
purpura (n = 2), livedo racemosa (n = 1), retiform
purpura and livedo racemosa (n = 1), and pernio-like
lesions, acrocyanosis, and petechiae (1).
Dermatopathology (Table IV) was available from 14
laboratory-confirmed cases (15 total biopsies). Six
patients with clinical retiform purpura and/or livedo
racemosa showed thrombotic vasculopathy. One pa-
tient with clinically described buttock pressure injury
also showed thrombotic vasculopathy. Another patient
with a complicated hospital course also developed
buttock pressure injury and retiform purpura, but the
biopsy showed only clotting and pressure necrosis.
One patient with palpable purpura with ulceration
showed leukocytoclastic vasculitis. Two patients with
papulosquamous morphologies showed spongiosis
and dermal inflammation. One patient with pernio-
like lesions had vacuolar interface dermatitis, subepi-
dermal edema, and superficial and deep lymphocytic
inflammation. One patient with an acrally distributed
petechial, macular, and urticarial eruption showed
diffuse vacuolar interface dermatitis with numerous
dyskeratotic keratinocytes, sparse perivascular
Abbreviations used:
AAD: American Academy of Dermatology
IQR: interquartile range
PCR: polymerase chain reaction
SARS-CoV-2: severe acute respiratory syndrome
coronavirus 2
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Table I. Characteristics of cases reported for new-onset dermatologic conditions in the setting of COVID-19
Characteristic
COVID-19 laboratory
confirmed* (n = 171)
COVID-19 clinically
suspected (n = 511) Total (N = 682)
Reporter title, n (%)
Dermatologist 81 (47) 289 (57) 370 (54)
Other physician 63 (37) 157 (31) 220 (32)
Physician assistant 12 (7.0) 16 (3.1) 28 (4.1)
Nurse practitioner 5 (2.9) 17 (3.3) 22 (3.2)
Nurse 8 (4.7) 11 (2.2) 19 (2.8)
Other medical professional 2 (1.2) 21 (4.1) 23 (3.4)
Patient age, y, median (IQR) 44 (28-61) 28 (18-42) 30 (19-49)
Patient sex, female, n (%) 93 (54) 260 (51) 353 (52)
Patient race/ethnicity, n (%)y
White 115 (67) 428 (84) 543 (80)
Asian 15 (8.8) 34 (6.7) 49 (7.2)
Black/African American 7 (4.1) 6 (1.2) 13 (1.9)
Hispanic/Latino 24 (14) 10 (1.2) 34 (5.0)
Missing 10 (5.8) 33 (6.5) 43 (6.3)
Patient geographic region, n (%)
North America
United States 148 (88) 458 (90) 606 (89)
Canada 2 (1.2) 17 (3.3) 19 (2.8)
Europe 10 (5.9) 25 (4.9) 35 (5.1)
Asia 6 (3.6) 6 (1.2) 12 (1.8)
Latin America and the Caribbean 2 (1.2) 4 (0.8) 6 (1.8)
Africa 1 (0.6) d 1 (0.1)
Oceania d 1 (0.2) 1 (0.1)
Condition type, n (%)
Skin 166 (97) 509 (100) 675 (99)
Edema 13 (7.6) 50 (9.8) 63 (9.2)
Mucous membrane 8 (4.7) 10 (2.0) 18 (2.6)
Hair 2 (1.2) 3 (0.6) 5 (0.7)
Nail 1 (0.6) 4 (0.8) 5 (0.7)
Morphology of skin change, n (%)
Pernio 31 (18) 391 (77) 422 (62)
Morbilliform 38 (22) 25 (4.9) 63 (9.2)
Urticarial 27 (16) 28 (5.5) 55 (8.1)
Macular erythema 23 (14) 29 (5.7) 52 (7.6)
Vesicular 18 (11) 31 (6.1) 49 (7.2)
Acrocyanosis 7 (4.1) 41 (8.0) 48 (7.0)
Acral desquamation 7 (4.1) 29 (5.7) 36 (5.3)
Papulosquamous 17 (9.9) 15 (2.9) 32 (4.7)
Livedo reticularis-like 9 (5.3) 15 (2.9) 24 (3.5)
Erythroderma 4 (2.3) 17 (3.3) 21 (3.1)
Grover-like 9 (5.3) 10 (2.0) 19 (2.8)
Retiform purpura 11 (6.4) 7 (1.4) 18 (2.6)
Petechial 5 (2.9) 11 (2.2) 16 (2.3)
Bullous 3 (1.8) 11 (2.2) 14 (2.1)
Palpable purpura/vasculitis 5 (2.9) 7 (1.4) 12 (1.8)
Dengue-like 6 (3.5) 5 (1.0) 11 (1.6)
Pressure injury 8 (4.7) 2 (0.4) 10 (1.5)
Pustular d 5 (1.0) 5 (0.7)
Erythema nodosum 2 (1.2) 3 (0.6) 5 (0.7)
Livedo racemosa 4 (2.3) d 4 (0.6)
Miliaria rubra 2 (1.2) 1 (0.2) 3 (0.4)
Multisystem inflammatory syndrome 1 (0.6) 1 (0.2) 2 (0.3)
Acneiform 1 (0.6) d 1 (0.1)
IQR, Interquartile range.
*Confirmed by polymerase chain reaction test, antibody test, or unspecified laboratory assay.
yQuestion not asked of all participants.
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lymphohistiocytic inflammation, and rare dermal
eosinophils.
DISCUSSION
This study highlights the wide variety of
cutaneous manifestations of COVID-19 reported
concurrently with or after COVID-19 diagnosis. The
most common morphologies in laboratory-
confirmed cases in our registry include morbilliform,
pernio-like, urticarial, macular erythematous, vesic-
ular, papulosquamous, and retiform purpura. Many
of these morphologies occur with different viral
infections and, thus, may not provide specific insight
into pathophysiology or treatment targets. However,
others may suggest potential immune or inflamma-
tory pathways involved in COVID-19 pathogenesis.
Furthermore, by documenting this constellation of
Table II. Dermatologic findings in patients with laboratory-confirmed COVID-19
Characteristics
Laboratory-confirmed COVID-19
Morbilliform
(n = 38)*
Pernio
(n = 31)
Urticarial
(n = 27)
Macular
erythema
(n = 23)
Vesicular
(n = 18)
Papulosquamous
(n = 17)
Retiform
purpura
(n = 11)
Age, y, median (IQR) 52 (36-66) 35 (22-59) 42 (29-54) 31 (27-55) 55 (36-58) 28 (27-38) 66 (51-73)
Female sex, n (%)y 19 (50) 16 (52) 21 (78) 16 (70) 10 (56) 7 (41) 2 (18)
Body site affected, n (%)
Face 8 (21) d 8 (30) 6 (26) 6 (33) 4 (24) d
Head (excluding face) 2 (5.3) d 4 (15) 1 (4.3) 1 (5.6) d d
Neck 10 (26) d 5 (19) 6 (26) 1 (5.6) 4 (24) d
Chest 19 (50) d 8 (30) 8 (35) 6 (33) 8 (47) d
Abdomen 24 (63) d 11 (41) 9 (39) 8 (44) 11 (65) d
Back 23 (61) d 11 (41) 11 (48) 6 (33) 11 (65) d
Arm 21 (55) d 13 (48) 11 (48) 8 (44) 11 (65) 2 (18)
Hand 7 (18) 10 (32) 7 (48) 4 (18) 7 (39) 3 (18) 3 (27)
Genitals 2 (5.3) d 1 (3.7) d 2 (11) 2 (12) d
Legs/buttocksz 22 (58) d 14 (52) 10 (44) 8 (44) 11 (65) 7 (64)
Foot 7 (18) 26 (84) 6 (22) 5 (22) 3 (17) 2 (12) 2 (18)
Entire body 4 (11) d 4 (15) 1 (4.3) d d d
Dermatologic symptoms, n (%)
Asymptomatic 8 (21) 3 (9.7) 1 (3.7) 4 (17) 2 (11) d 8 (73)
Pain/burning 6 (16) 22 (71) 6 (22) 6 (26) 9 (50) 5 (29) 1 (9.1)
Pruritus 23 (61) 11 (36) 20 (74) 14 (61) 13 (72) 16 (94) d
Timing of dermatologic changes,
n (%)
Before COVID-19 symptoms 3 (7.9) 5 (16) 2 (7.4) 2 (8.7) 1 (5.6) 3 (17.6) 1 (9.1)
After COVID-19 symptoms 29 (76) 15 (48) 18 (67) 13 (57) 13 (72) 9 (53) 10 (91)
At the same time as COVID-19 5 (13) 3 (9.7) 6 (22) 7 (30) 4 (22) 4 (24) d
No other COVID-19 symptoms 1 (2.6) 6 (19) 1 (3.7) 1 (4.3) d 1 (5.9) d
Most likely etiology, as determined
by health care provider, n (%)x
COVID-19 related 27 (71) 28 (90) 20 (74) 21 (91) 16 (89) 13 (77) 9 (82)
Related to another virus 4 (11) 2 (6.5) 4 (15) d d 2 (12) d
Postviral rash 6 (16) d 3 (11) 1 (4.3) 2 (11) 2 (12) d
Unsure 1 (2.6) 1 (3.2) d 1 (4.3) d d 2 (18)
Comorbid dermatologic condition
Contact dermatitis 1 (2.6) d d 1 (4.3) d 3 (18) d
Alopecia areata d d 1 (3.7) 1 (4.3) d 2 (12) d
Melanoma 2 (5.3) 1 (3.2) d d d d d
Hidradenitis suppurativa d 1 (3.2) d d 1 (5.6) d d
IQR, Interquartile range.
*Because providers could select more than 1 rash morphology, some patients are double counted (ie, patient had both morbilliform rash
and pernio).
yDefined as sex assigned at birth.
zLegs and buttocks were combined because of the questionnaire design, which changed slightly over the course of the study.
xCases determined to be due to a drug have been excluded from this table and are included in the Supplemental Materials (available via
Mendeley at http://doi.org/10.17632/gh945hpwy3.1).
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Table III. COVID-19erelated characteristics of patients with laboratory-confirmed COVID-19 and new-onset
dermatologic conditions
Characteristics
Laboratory-confirmed COVID-19
Morbilliform
(n = 38)*
Pernio
(n = 31)
Urticarial
(n = 27)
Macular
erythema
(n = 23)
Vesicular
(n = 18)
Papulosquamous
(n = 17)
Retiform
purpura
(n = 11)
COVID-19 diagnosis, n (%)
PCR 32 (84) 16 (52) 23 (85) 19 (83) 16 (89) 14 (82) 10 (91)
Antibody d 11 (35)y d 2 (8.7) 1 (5.5) 3 (18) d
Unspecified laboratory assay 6 (16) 4 (13) 4 (15) 2 (8.7) 1 (5.5) d 1 (9)
COVID-19 exposure, n (%)
None 9 (24) 11 (36) 9 (33) 7 (30) 4 (22) 6 (35) 6 (55)
Unknown 13 (34) 7 (23) 6 (22) 5 (22) 5 (28) 4 (24) 3 (27)
Close contact with a
laboratory-confirmed
case of COVID-19 infection
9 (24) 5 (16) 7 (26) 7 (30) 3 (17) 4 (24) 1 (9.1)
Close contact with a probable
case of COVID-19 infection
5 (13) 7 (23) 4 (15) 3 (13) 3 (17) 3 (18) d
Presence in a health care facility where
COVID-19 infections have been
managed
8 (21) 1 (3.2) 5 (19) 2 (8.7) 3 (17) 1 (5.9) 1 (9.1)
COVID-19 symptoms, n (%)
Fever 28 (74) 11 (35) 19 (70) 15 (65) 13 (72) 10 (59) 7 (64)
Cough 25 (66) 11 (35) 16 (59) 12 (52) 11 (61) 9 (53) 8 (73)
Shortness of breath 17 (45) 9 (29) 11 (41) 9 (39) 5 (28) 5 (29) 8 (73)
Sore throat 15 (40) 8 (26) 11 (41) 9 (39) 9 (50) 7 (41) 3 (27)
Headache 14 (37) 7 (23) 13 (48) 7 (30) 6 (33) 7 (41) d
Diarrhea, vomiting, or nausea 15 (40) 7 (23) 10 (37) 9 (39) 5 (28) 5 (29) d
Malaise 12 (32) 5 (16) 8 (30) 9 (39) 6 (33) 2 (12) 3 (27)
Myalgia 8 (21) 10 (32) 9 (33) 2 (8.7) 4 (22) 2 (12) d
Irritability/confusion 5 (13) 3 (9.7) 5 (19) 4 (17) 6 (33) 4 (24) d
Chest pain 2 (5.3) 2 (6.5) 7 (26) 5 (22) 4 (22) 5 (29) d
Abdominal pain 1 (2.6) 1 (3.2) 7 (26) 5 (22) 5 (28) 4 (24) d
Anosmia 3 (7.9) 3 (9.7) 2 (7.4) 3 (13) 5 (28) 2 (12) d
Dysgeusia 1 (2.6) 2 (6.5) 5 (19) d 2 (11) 2 (12) d
Arthralgia 7 (18) 1 (3.2) 3 (11) 1 (4.3) 3 (17) d 1 (9.1)
Rhinorrhea 3 (7.9) 5 (16) 4 (15) 1 (4.3) 1 (5.6) d d
Asymptomatic 1 (2.6) 6 (19) 2 (7.4) d d 2 (12) d
COVID-19 testing criteria, n (%)z
Does not meet CDC testing criteria 2 (5.3) 9 (29) 2 (7.4) 1 (4.3) d 2 (12) d
1 or 2 CDC testing criteria 15 (40) 13 (42) 6 (22) 5 (22) 7 (39) 8 (47) 6 (55)
3 or more CDC testing criteria 21 (55) 9 (29) 19 (70) 17 (74) 11 (61) 7 (41) 5 (46)
COVID-19 treatment, n (%)
Supportive care only 19 (50) 21 (68) 16 (59) 14 (61) 11 (61) 15 (88) d
Antimalarial agents 13 (34) 3 (9.7) 6 (22) 4 (17) 4 (22) 1 (5.9) 10 (91)
Antibiotics 11 (29) 4 (13) 6 (22) 6 (26) 4 (22) d 9 (82)
Bevacizumab 5 (13) d 4 (15) 1 (4.3) 2 (11) d d
Remdesivir 2 (5.3) 1 (3.2) 2 (7.4) 1 (4.3) 1 (5.6) 1 (5.9) 1 (9.1)
Serpin inhibitors 1 (2.6) 1 (3.2) 1 (3.7) d 1 (5.6) 2 (12) d
IL-6 inhibitors d d 1 (3.7) d 1 (5.6) d 2 (18)
Lopinavir/ritonavir 1 (2.6) d 1 (3.7) d d d d
JAK inhibitors d 2 (6.5) d d d d d
COVID-19 level of care, n (%)
Outpatient care only 21 (55) 26 (84) 18 (67) 14 (61) 14 (78) 16 (94) 0
Hospitalized
No supplemental oxygen 5 (13) 2 (6.5) 5 (19) 1 (4.3) 3 (17) 1 (5.9) 0
Supplemental oxygen only 6 (16) d 2 (7.4) 4 (17) d d 1 (9.1)
Continued
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cutaneousmanifestations, we hope to help providers
more accurately identify signs of COVID-19.
Cutaneous COVID-19 manifestations generally
presented simultaneous to or after other COVID-19
symptoms. However, 12% occurred before other
COVID-19 signs, highlighting their importance in
assisting COVID-19 detection.
Similar to previous reports, pernio-like lesions
were reported more than other dermatologic
manifestations.1,7,9 The high frequency of these re-
ports may reflect the media attention pernio-like
lesions received, especially in April/May 2020, with
providers potentially sensitized to enter cases even
without laboratory confirmation.18,19 However, when
restricted to laboratory-confirmed subgroup analysis,
morbilliform and/or macular erythema presentations
were more common. Similarly, a Spanish case series
reported half of laboratory-confirmed COVID-19
dermatologic manifestations as maculopapular, 19%
as pernio-like, and 19% as urticarial.6
Thirty-one patients with pernio-like lesions had
laboratory-confirmed COVID-19dincluding 16 who
had positive results on PCRdand, therefore, were
possibly infectious. Given public health risks posed
by COVID-19, new onset of pernio-like lesions
should prompt patient-provider discussions
regarding both testing with PCR and/or antibody
assays and the role of self-isolation in concordance
with local and national guidelines. Reassuringly,
pernio-like lesions usually appeared in patients
with relatively mild COVID-19 disease courses; these
patients had fewer other COVID-19 symptoms and
lesser severity (5/31 hospitalized, 2 deaths). How this
relates to immune response to the virus and
likelihood for complications remains unclear. If not
coincidental, perhaps the underlying mechanism
that predisposed patients to pernio-like lesions is
protective, suggesting that perniomay be amarker of
a robust, effective host antiviral response limiting
COVID-19 complications.7 Although we cannot
completely exclude epiphenomena, because
patients may notice foot lesions more and be more
likely to seek care, this cluster is unusual. New cases
appeared in geographies where winter temperatures
remained [108C and continue even during late
spring’s warmer weather.
Table III. Cont’d
Characteristics
Laboratory-confirmed COVID-19
Morbilliform
(n = 38)*
Pernio
(n = 31)
Urticarial
(n = 27)
Macular
erythema
(n = 23)
Vesicular
(n = 18)
Papulosquamous
(n = 17)
Retiform
purpura
(n = 11)
Noninvasive ventilation or
high flow oxygen
d 1 (3.2) 0 d d d 0
Ventilator and/or ECMO required 6 (16) 1 (3.2) 2 (17.4) 4 (17) 1 (5.6) d 10 (91)
COVID-19 complications, n (%)
None 27 (71) 26 (84) 24 (89) 17 (74) 17 (94) 17 (100) d
ARDS 4 (11) 1 (3.2) 1 (3.7) 4 (17) 1 (5.6) d 9 (82)
Thrombotic event 3 (7.9) 2 (6.5) d 1 (4.3) d d 7 (64)
Other infection 1 (2.6) 1 (3.2) 2 (7.4) 1 (4.3) d d 6 (55)
Sepsis 4 (11) d 0 2 (8.7) d d 2 (18)
Acute kidney injury 3 (7.9) d d 2 (8.7) d d 2 (18)
Death 1 (2.6) 2 (6.5) 1 (3.7) 1 (4.4) d d 3 (27)
Comorbid medical conditions, n (%)
None 21 (55) 21 (68) 17 (63) 13 (57) 12 (67) 13 (77) 2 (18)
Hypertension 8 (21) 4 (13) 3 (11) 4 (17) 3 (17) 3 (18) 7 (64)
Diabetes 7 (18) d 4 (15) 1 (4.3) 2 (11) 1 (5.9) 4 (36)
Obstructive lung disease 3 (7.9) d 1 (3.7) 2 (8.7) 1 (5.6) 1 (5.9) 6 (55)
Other lung disease 3 (7.9) 1 (3.2) 3 (11) 1 (4.3) 1 (5.6) d d
Rheumatologic disease 1 (2.6) 2 (6.5) d d 1 (5.6) d 1 (9.1)
Cardiovascular disease 2 (5.3) 1 (3.2) d 1 (4.3) d d 1 (9.1)
Kidney disease 1 (2.6) d d 2 (8.7) d 2 (12) d
ARDS, Acute respiratory distress syndrome; CDC, Centers for Disease Control and Prevention; ECMO, extracorporeal membrane oxygenation;
IL, interleukin; JAK, Janus kinase; PCR, polymerase chain reaction.
*Because providers could select more than 1 rash morphology, some patients are double counted (ie, a patient had both morbilliform rash
and pernio).
yImmunoglobulin (Ig) M positive, IgG negative: n = 5; IgM negative, IgG positive: n = 1; IgM unknown, IgG positive: n = 1; unknown type of
antibodies tested: n = 4.
zCDC testing criteria reviewed as of May 15, 2020, included fever, cough, sore throat, shortness of breath, myalgia, dysgeusia, anosmia, and
vomiting/diarrhea.
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Of patients with other dermatologic manifesta-
tions of COVID-19, including morbilliform
eruptions, macular erythema, urticaria, and vesicular
rashes, 22% to 45% were hospitalized, with 3 deaths.
However, fixed livedo racemosa, retiform purpura,
and true acral ischemia appeared in critically ill
patients, corroborating others’ findings.6,14 Given
the occurrence on acral surfaces, these
morphologies should be distinguished from
pernio-like lesions. In acral livedo racemosa,
retiform purpura, and acro-ischemia, the histopath-
ologic findings presented here show noninflamma-
tory to pauci-inflammatory thrombi without other
findings often associated with pernio, such as
vacuolar interface changes with associated necrotic
keratinocytes, papillary derma edema, and a
superficial and deep dermal lymphocytic infiltrate.
This suggests that thrombotic disease in critically ill
patients with COVID-19 may extend to the skin in
patients with livedo racemosa/retiform purpura/
acro-ischemia, with a morphology distinct from
pernio.14 One study implicated activation of the
alternative complement pathway cutaneous
thrombosis pathophysiology.14 Placentas in mothers
with mild COVID-19 showed no viral infection but
abnormal thrombus formation in the absence of
complement activation, suggesting that systemic
coagulopathy may not involve complement pathway
activation in all patients.20 Why some patients
develop severe coagulopathy but others do not
remains under active investigation.
Accurate evaluation and morphologic descrip-
tions of subtle physical examination findings,
including consideration of whether lesions are
appropriate for skin biopsy, are important in
evaluating acral lesions in patients with known/
suspected COVID-19. This nuance is especially true
in patients with skin of color, for whom the
examination of frank erythema and pernio-like
lesions may be challenging. In darker skin types
(Fitzpatrick IV-VI), more assiduous examination is
important because erythema may clinically manifest
as subtler dark purple/brown hyperpigmentation.
Beyond assisting with clinical examination, we
sought to identify dermatologic manifestations of
COVID-19 to improve understanding of SARS-CoV-2
pathophysiology. Previously, Suchonwanit et al21
proposed that cutaneous manifestations in
COVID-19 may present in 2 mechanistic patterns:
(1) clinical features similar to viral exanthems, an
immune response to viral nucleotides and
(2) cutaneous eruptions secondary to COVID-19
systemic consequences, especially vasculitis and
thrombotic vasculopathy. Although this suggested
dichotomy is a loose framework, it may prove a good
starting point to consider our findings.
For instance, pernio-like lesions may offer an
opportunity for deeper understanding of both the
Severity of COVID-19* 
*Severity calculated based on percentage of patients hospitalized for COVID-19
Pernio Retiform purpuraVesicular/ Urticarial/ Macular Erythema/ Morbilliform
• Feet (84%) and hands 
  (32%)
• Pain/burning (71%) 
  and pruritus (36%)
• After other COVID-
  19 symptoms (49%)
• Fever (35%), cough 
  (35%);19% asymptomatic
• 16% hospitalized
• Extremities and buttocks
• Often asymptomatic (73%)
• After other COVID
  -19 symptoms (91%)
• Fever (64%), cough 
  (73%), and shortness of 
  breath (73%) 
• 100% hospitalized
• 82% with ARDS
• Trunk and extremities
• Pruritus in 61-74%
• Typically after other COVID-19 symptoms (19%)
• Fever (65-74%), cough (52-66%), 
  sore throat (39-50%), shortness of breath (28-45%)
• 22-45% hospitalized across groups
Fig 1. The spectrum of COVID-19 dermatologic manifestations in all patients, with severity of
disease calculated based on the percentage of patients with each condition who were
hospitalized. ARDS, Acute respiratory distress syndrome.
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Table IV. Histologic findings of dermatologic conditions in patients with laboratory-confirmed COVID-19*
Clinical lesion morphology
Laboratory-confirmed COVID-19
Additional clinical details Type of COVID-19 testing Histologic findings
Thrombotic vasculopathy
Retiform purpura Patient required invasive
mechanical ventilation. His
course was complicated by
ARDS, pulmonary
embolism, and retiform
purpura on the hands, legs,
and feet.
PCR positive Thrombotic vasculopathy
Retiform purpura and
livedo reticularis
Patient required invasive
mechanical ventilation. His
course was complicated by
ARDS, pulmonary
embolism, and retiform
purpura and livedo
reticularis of the arm.
PCR positive Thrombotic vasculopathy
Retiform purpura Patient was hospitalized and
required invasive
mechanical ventilation.
Course was complicated by
ARDS, DVT, and retiform
purpura of the buttocks.
PCR positive Pauci-inflammatory
thrombotic vasculopathy
Livedo reticularis Patient was hospitalized and
required invasive
mechanical ventilation.
Eight days later, she
developed livedo
reticularis.
PCR positive Pauci-inflammatory
thrombotic vasculopathy
Livedo racemosa Patient required invasive
mechanical ventilation, and
her course was complicated
by ARDS, pulmonary
embolism, secondary
infection, and livedo
racemosa of the hand.
PCR positive Thrombotic vasculopathy
Livedo racemosa Patient required invasive
mechanical ventilation.
Hospital course was
complicated by ARDS,
pulmonary embolism,
secondary infection, and
asymptomatic livedo
racemosa of the arm.
PCR positive Pauci-inflammatory
thrombotic vasculopathy
Morbilliform rash, macular
erythema, and pressure
injury
At the same time as COVID-19
symptoms, patient
developed morbilliform
rash and macular erythema
over the trunk. The patient
required invasive
mechanical ventilation and
developed what appeared
to be pressure injury on the
buttocks.
PCR positive Biopsy 1 (abdomen): interface
dermatitis;
differential diagnosis
includes a drug eruption
and viral exanthem.
Biopsy 2 (buttock):
thrombotic vasculopathy
Continued
J AM ACAD DERMATOL
VOLUME jj, NUMBER j
Freeman et al 9
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Table IV. Cont’d
Clinical lesion morphology
Laboratory-confirmed COVID-19
Additional clinical details Type of COVID-19 testing Histologic findings
Skin necrosis
Retiform purpura and
pressure injury
Patient required invasive
mechanical ventilation.
Hospital course was
complicated by ARDS,
secondary infection, and
then retiform purpura plus
pressure injury on the
buttocks.
PCR positive Clotting and pressure-
induced necrosis
LCV
Palpable purpura and
acral desquamation
Patient developed red itchy
rash after COVID-19
symptoms, which
worsened with erosions
and painful ulceration
IgM positive LCV
Spongiosis
Papulosquamous Patient developed unilateral
rash on anterior shin.
Patient was not
hospitalized and required
no treatment.
PCR positive Spongiosis with
hyperkeratosis, edema,
perivascular lymphocytes,
neutrophils, extravasated
erythrocytes
Papulosquamous Patient presented to
dermatology 30 days after
onset of COVID-19
symptoms with a
papulosquamous eruption.
PCR positive Favor pityriasis rosea;
histologic differential
diagnosis includes viral
exanthem, contact
dermatitis, or eczema
Other
Pernio-like Patient presented with painful
pernio-like lesions of the
fingers and toes.
PCR positive Mild vacuolar interface
dermatitis, subepidermal
edema, and superficial/
deep lymphocytic
inflammation. Differential
diagnosis: perniosis,
autoimmune CTD such as
dermatomyositis, and SLE
Morbilliform, urticarial,
and petechial
Patient was hospitalized, was
intubated, and developed
acral distributed petechial,
macular, and urticarial rash
3 to 4 weeks after COVID-19
symptoms.
PCR positive Diffuse vacuolar interface
dermatitis with numerous
dyskeratotic keratinocytes
predominantly localized to
the basal layer, with
lymphocyte exocytosis and
sparse superficial
perivascular
lymphohistiocytic
inflammation with rare
eosinophils
Pernio and Grover-like Two weeks after COVID-19
symptoms, patient
developed Grover-like rash
and pernio
IgM positive;
PCR negative
Granulomatous dermatitis
(colloidal iron showed
increased mucin deposition
within the center of the
granuloma)
ARDS, Acute respiratory distress syndrome; CTD, connective tissue disease; DVT, deep vein thrombosis; Ig, immunoglobulin;
LCV, leukocytoclastic vasculitis; PCR, polymerase chain reaction; SLE, systemic lupus erythematosus.
*The cases have been grouped in the table by predominant histologic finding.
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pathophysiology of SARS-CoV-2 and pernio as a
reaction pattern with multiple etiologies. The
underlying cause of pernio-like lesions from the
pathology collected suggests a primary inflammatory
process. Pernio-like lesions are generally
nonischemic and, thus far, do not suggest systemic
intravascular thromboses, unlike retiform purpura
and acral ischemia. Interferonopathies, genetic con-
ditions with overproduction of type I interferons,
may present with pernio-like lesions, suggesting a
robust interferon response in the pathogenesis of
perniosis.22 Type I interferon is critical for antiviral
immunity, and thus, its heightened production in
young, healthy people exposed to SARS-CoV-2 is
expected and would lead to successful viral control
but also, hypothetically, could trigger pernio.23
Indeed, a low/delayed interferon response might
allow for uncontrolled viral replication and a
subsequent cytokine storm leading to severe illness
and low incidence of pernio.23 SARS-CoV-2e
infected Chinese patients with interferon-induced
transmembrane protein 3 gene polymorphism may
develop worsening disease in an age-dependent
fashion, suggesting that an interferon-driven antiviral
response could be necessary for early viral control.24
Our study is limited by the constraints of a case
series, which cannot accurately estimate the
prevalence or incidence of these findings. The
incidence of COVID-19 dermatologic manifestation
remains unclear, with studies reporting 0.2% to
20%.8,25,26 There also remains the possibility of bias
due to attribution error, given the reliance on
providers’ judgment in entering data regarding
whether findings were virus related, were from a
medication, or were from other causes. Although
providers were prompted for case updates, most
reports represent a single snapshot, preventing full
observation of dermatologic manifestations, disease
complications, and follow-up testing. Limited testing
of COVID-19 remains a persistent issue. Only 25% of
our patients had laboratory-confirmed disease. It is
difficult to parse the effects of poor test access and
false negative tests on our data. Furthermore, this
registry represents a small sample of global
dermatologic manifestations; US dermatology
networks received themost promotion, as our results
reflect. Additionally, providers may have been more
likely to enter more severe cases.
The lack of a clear definition for COVID-19e
associated skin findings may restrict extrapolation
from these data, such as, the nonspecific term COVID
toes, whichmay incorporate a variety of acral lesions.
Only half of medical professionals entering cases
were dermatologists, making morphologic misclas-
sification possible; without photographs to confirm,
we cannot ensure consistent description. As more
data emerge, we should examine specific subsets
(eg, angulated distal purpura, erythema multiforme-
like lesions, and true pernio-like lesions) that may
have distinct clinical morphologies, histologic pat-
terns, and pathophysiology. Nevertheless, we
believe that better recognition of these manifesta-
tions, whether from the disease itself or from
medications for COVID-19, will provide insight into
disease characterization and management.27
Our cases lacked diversity in representation, with
only 34 Hispanic/Latino and 13 Black/African
American patients. This poor racial/ethnic diversity
in the classification of COVID-19 dermatologic
manifestations is problematic, especially given that
photos of these lesions in darker skin types may help
patients and providers identify early signs of
COVID-19.28 Disparities in the number of
COVID-19 hospitalizations and outcomes show a
disproportionate impact on these populations.29
Lack of race and ethnicity data reporting in state
health department registries of COVID-19 cases has
complicated this issue.30 Early recognition,
diagnosis, and management of cutaneous
manifestations of COVID-19 in patients with skin of
color provides an additional way in which health
care providers can help care for underrepresented
minority populations, thereby reducing the health
care disparities seen with COVID-19.
In conclusion, we show a spectrum of
COVID-19erelated dermatoses. These cutaneous
manifestations may present with other COVID-19
symptoms, and others may represent postviral
inflammatory responses. Our study highlights that
pernio-like lesions are associated with milder
COVID-19 disease courses, whereas retiform pur-
pura is associated with severe disease in critically ill
patients. Further investigation is needed to precisely
ascertain the timing of findings, the pathophysiology
behind different morphologies, and potential anti-
body response in patients who may have only mild
COVID-19 symptoms.31-35 Dermatologic findings
should not be overlooked as signs of COVID-19
and should prompt discussions between physicians
and patients regarding isolation and possible testing.
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